DCISionRT is intended for women with DCIS considering BCS. The test reports a patient’s 10-year risk of recurrence and predicts RT benefit.
DecisionDx-SCC is a genomic test that was developed to predict metastatic risk for SCC patients with one or more risk factors. The test classifies patients as low (Class 1), higher (Class 2A) or highest (Class 2B) biological risk of metastasis.